Interferons — CPB 0404 | AETNA Coverage Update

Aetna modified CPB 0404 covering interferons — including Actimmune (J9216) and Pegasys (S0145) — effective January 11, 2026. Here's what billing teams need to know.

Aetna, a CVS Health company, updated its interferon coverage policy under CPB 0404 to clarify medical necessity criteria across three distinct drug categories: interferon gamma-1b (Actimmune), peginterferon alfa-2a (Pegasys), and ropeginterferon alfa-2b-njft (Besremi). The update touches prior authorization requirements, prescriber specialty restrictions, and a broad set of covered indications. If your practice bills HCPCS J9216 or S0145, or runs hepatitis C viral load testing under CPT 87520–87522, this policy affects your reimbursement.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Interferons — CPB 0404
Policy Code	CPB 0404
Change Type	Modified
Effective Date	January 11, 2026
Impact Level	High
Specialties Affected	Immunology, oncology, hematology, hepatology, endocrinology, transplant medicine
Key Action	Audit all interferon claims for prescriber specialty match and indication alignment before submitting against the January 11, 2026 effective date

---

Aetna Interferon Coverage Criteria and Medical Necessity Requirements 2026

CPB 0404 splits criteria by drug. Each agent has its own approval rules, covered indications, and continuation requirements. Treat them as three separate policies housed under one code.

Interferon Gamma-1b (Actimmune) — HCPCS J9216

Aetna covers J9216 for three indications only. Medical necessity requires one of these diagnoses:

#	Covered Indication Copy
1	Chronic granulomatous disease (CGD) — to reduce infection frequency and severity
2	Mycosis fungoides/Sézary syndrome — for active treatment
3	Severe, malignant osteopetrosis (SMO) — to delay disease progression

The prescriber specialty requirement here is real and enforced. Actimmune for CGD must come from an immunologist or a prescriber who specializes in CGD management. SMO requires an endocrinologist. Mycosis fungoides/Sézary syndrome requires a hematologist or oncologist. If the prescribing specialty doesn't match the indication, expect a claim denial.

Continuation of Actimmune therapy requires documented evidence of benefit — disease stability or improvement. Document this at every renewal. Aetna will not approve ongoing therapy without it.

Peginterferon Alfa-2a (Pegasys) — HCPCS S0145

Pegasys has the widest covered indication list in CPB 0404. Aetna's coverage policy includes 11 approved uses. For hepatitis B (ICD-10 B18.0, B18.1), Pegasys is covered up to 48 weeks total. Beyond 48 weeks, Aetna calls it experimental — full stop.

Hepatitis C (B18.2) and hepatitis E (B18.8) are also covered, but HEV has two hard requirements: the member must be a liver transplant recipient, and they must have failed, been intolerant of, or have a contraindication to ribavirin. Both criteria must be documented before you submit.

Continuation criteria for Pegasys vary by indication. HBV, HCV, and HEV in transplant patients must re-meet all initial criteria at every continuation request. Myeloproliferative neoplasms and systemic mastocytosis require documented disease stability or improvement. For all other covered indications, continuation requires no evidence of unacceptable toxicity or disease progression.

If you bill CPT 87520, 87521, or 87522 for hepatitis C viral load testing alongside Pegasys, confirm these codes are linked to the HCV diagnosis in your claim. Payers use viral load results to substantiate medical necessity for continued treatment.

Ropeginterferon Alfa-2b-njft (Besremi)

The policy summary for Besremi covers polycythemia vera as the primary indication. The full criteria were truncated in the available data. If your practice treats polycythemia vera patients with Besremi, pull the complete CPB 0404 text from Aetna directly and confirm the current criteria before submitting claims. Don't rely on a summary here — the full policy has the specifics you need for prior authorization.

---

Aetna Interferon Exclusions and Non-Covered Indications

Any indication not listed in CPB 0404's covered sections is considered experimental, investigational, or unproven by Aetna. This isn't vague — Aetna states it explicitly for each drug.

For Actimmune (J9216), that means any use outside CGD, mycosis fungoides/Sézary syndrome, and severe malignant osteopetrosis is not covered. Off-label uses like pulmonary fibrosis or cystic fibrosis will be denied.

For Pegasys (S0145), all uses outside the 11 listed indications are excluded. Chronic hepatitis B treatment beyond 48 weeks is specifically called out as experimental — not just uncovered, but actively flagged.

This matters for your prior authorization workflow. If you're submitting a PA for an indication that's not on the covered list, you're not going to get it approved through standard channels. That's a prior auth appeal situation, not a documentation fix.

---

Coverage Indications at a Glance

Consult your payer agreement for prior authorization requirements, which may apply to these medical necessity criteria. For ICD-10 code mapping by indication, see the full CPB 0404 ICD-10 code list (280 codes) at PayerPolicy — do not rely on indication-level code assignments not confirmed in the source policy.

---

Aetna Interferon Billing Guidelines and Action Items 2026

These steps apply now. The effective date is January 11, 2026 — policies are already in force.

Copy Action Items

If you manage a high volume of interferon claims across multiple indications and aren't sure how this update interacts with your current authorization workflow, talk to your compliance officer before you hit a denial cycle. The prescriber specialty rules alone create denial exposure that's easy to miss in a busy practice.

---

CPT, HCPCS, and ICD-10 Codes for Interferons Under CPB 0404

Covered HCPCS Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
J9216	HCPCS	Injection, interferon, gamma-1b, 3 million units
S0145	HCPCS	Injection, pegylated interferon alfa-2a, 180 mcg per ml

Key ICD-10-CM Diagnosis Codes

The full ICD-10 list under CPB 0404 contains 280 codes spanning a wide range of oncologic, infectious, and inflammatory diagnoses. Pull the complete code list from the full CPB 0404 policy on PayerPolicy before finalizing your charge capture mapping.

---